FLT3 and acute myeloid leukemia: The first-in-class agent midostaurin, a multikinase type I inhibitor, demonstrated a survival benefit when combined with standard chemotherapy in newly diagnosed FLT3-mutated AML, establishing FLT3 inhibition as a validated therapeutic strategy.